How Investors May Respond To Arrowhead Stock Phase 3 Trial Results
- Arrowhead Pharmaceuticals reported that its Phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran in severe hypertriglyceridemia met all primary and prespecified secondary endpoints, with deep triglyceride reductions, fewer acute pancreatitis events, and a safety profile comparable to placebo.
- The company now intends to file a supplemental New Drug Application by the end of 2026. This filing could extend REDEMPLO’s reach beyond familial chylomicronemia syndrome into a broader severe hypertriglyceridemia population and could change Arrowhead’s future revenue mix.
- With plozasiran’s Phase 3 data showing large and durable triglyceride reductions, this development may have implications for Arrowhead Pharmaceuticals’ overall investment narrative.
Scan opportunities beyond Arrowhead Pharmaceuticals by reviewing the hand picked 36 healthcare AI stocks.
Arrowhead Pharmaceuticals Investment Narrative Recap
To own Arrowhead Pharmaceuticals, you need to believe the RNAi platform can translate late stage assets into durable product franchises while the company manages heavy R&D and commercial build out costs. The key near term catalyst remains regulatory progress and commercial execution around plozasiran, including the planned supplemental filing in severe hypertriglyceridemia. SHASTA 3 and SHASTA 4 success supports that thesis clinically but does not remove the usual regulatory timing and reimbursement uncertainties. The biggest near term risk still centers on cash burn and reliance on partnership and milestone flows while Arrowhead remains unprofitable.
The recent SHASTA 3 and SHASTA 4 announcement ties directly to the prior update that Arrowhead plans a supplemental New Drug Application for plozasiran by year end 2026 and intends to use a Priority Review Voucher. That operational step could be an important bridge from an orphan FCS indication toward a wider severe hypertriglyceridemia setting, with potential implications for the revenue mix if approval and uptake follow. Execution risk remains. Arrowhead must scale manufacturing, support a self injection regimen, work with payers and still keep multiple other RNAi programs moving through the clinic.
That said, the cleaner story around plozasiran does not solve the trickiest issue that still hangs over Arrowhead...
Read the full Arrowhead Pharmaceuticals narrative to see the case behind these numbers.
Arrowhead Pharmaceuticals' narrative projects US$1.0b revenue and US$176.0 million earnings by 2029. This implies 15.7% yearly revenue growth and an earnings improvement of US$496.0 million from a loss of US$320.0 million today.
Arrowhead Pharmaceuticals' forecasts point to a fair value of $110.18 compared with the $85.11 share price, representing a 29% upside to its current price that could narrow quickly.
Exploring Other Perspectives
Some of the lowest Arrowhead Pharmaceuticals forecasts focus on tougher reimbursement rather than trial success. Those analysts were pencilling in revenue of about US$403.8 million and earnings of US$71.8 million by 2029, with a steep 275.4x P/E. This can be read as a far more cautious story that may shift after the SHASTA data.
To see how other investors frame Arrowhead Pharmaceuticals' potential, compare its current price with 2 other fair value estimates for Arrowhead Pharmaceuticals.
Reach Your Own Conclusion
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
- A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- See our latest analysis for Arrowhead Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Arrowhead Pharmaceuticals' overall financial health at a glance.
Looking For More Investment Ideas Beyond Arrowhead Pharmaceuticals?
Once you have a view on Arrowhead Pharmaceuticals, it can help to widen the lens and compare it with other opportunities using the Simply Wall St Screener. That way you see how different balance sheets, cash flows, and income profiles stack up side by side.
- If capital preservation is high on your list, start with companies that screen for lower overall risk profiles and review the 82 resilient stocks with low risk scores to see which businesses fit that brief.
- For investors hunting for potential value opportunities, check companies that pair quality fundamentals with attractive pricing using the 49 high quality undervalued stocks.
- If you care about financial resilience and want cleaner balance sheets, compare candidates on debt, cash, and liquidity using the list of solid balance sheet and fundamentals (24 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com